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year changes in the ratio were beneficially affected by lifestyle factors, but only to a mod- 
est degree. It is concerning that obesity at baseline contributes to a significant worsening 
of the ratio whereas a report of exercise only slightly improves the ratio. 
1202-88 Cholesterol Screening of Adults In the US: Role of 
Socio-demographic Factors 
(~hri~;tooher R. Bartalos, Chad Sun, Jacqueline S. Madnac, The University of Health 
Sciences, Kansas Ci~ Missouri, Medical Center of Independence, Independence, 
Missouri. 
Background: The National Cholesterol Education Program (NCEP) II & Expert Panel 
Adult Treatment Panel Ill (ATPIII) guidelines recommend a cholesterol screen every 5 
years for all adults ->20 yrs age, No information regarding the role of socio-demographic 
factors on US adult cholesterol screening has been published. 
Methods and Results: Data were extracted from the 1999 CDC Behavioral Risk Factor 
Surveillance System (BRFSS) survey. The SRFSS telephone surveyed 159,000 US 
adults regarding cholesterol screening within the last 5 years. Data were stratified by 
age, gender, ethnicity, income, education, level of insurance and the ability to afford 
health care. Overall 69% adults were screened within the last 5 yrs, which is below the 
Healthy People 2000/2010 goals of 75% & 80% respectively, However 85% adults >65 
years were screened. Adults aged _>45 years were 3.7 times more likely to receive cho- 
lesterol screening. Those with health insurance were 2.4 times more likely to receive 
screening. High school graduates or those with some college were 1.5 times more likely 
to be screened. Women were 1.2 times more likely to be screened, Those with an 
income _>$20K/yr were 1.4 times more likely to receive screening. The socio-demo- 
graphic variables had a compounding influence on cholesterol screening. For example, 
the individual <45 yrs age, who was less educated, with a lower economic status and had 
no health insurance was the least likely to report having received cholestero~ screening 
within the last 5 years (29%). 
Conclusion: Socio-demographic factors play an important role in cholesterol screening. 
This information may be used for targeted future cholesterol screening interventions. 
1202-89 Contemporary Awareness and Understanding of 
Cholesterol as a Risk Factor: Results of an American 
Heart Associat ion National Survey 
Ira S, Nash. Lori Mosca, Roger S. Blumenthal, Michael Davidson, Sidney C. Smith, 
Richard C. Pasternak, Mount Sinai School of Medicine, New York, New York. 
Public awareness and understanding of risk factors for atherosclerotic vascular disease 
are essential for successful primary and secondary prevention. The American Heart 
Association conducted a national telephone survey to assess public knowledge of the 
link between cholesterol and heart disease and the specifics of cholesterol management 
in April 2001. A national probability sample of 1114 adults age 40 years and older was 
interviewed by trained personnel using a structured format. Good regional distribution 
was achieved; 29% of respondents were over age 65, 56% were women and 87% were 
white. Most (55%) were employed and of those, 70% identified themselves as white-col- 
lar workers. Over 90% had at least a high school education and over 30% completed col- 
Ioge, Although 91% stated that it was "important o them personally to have a healthy 
cholesterol evel" (77% extremely or very important), 51% did not know their own level 
Only 40% were aware of national guidelines for cholesterol management, and 52% could 
not identify the correct desirable total cholesterol evel for a healthy adult. More people 
selected HDL than LDL as the most important lipid fraction to control (22% vs 16%). 
When asked what sources of information they rely on the most, 67% identified physicians 
and 13% stated magazines were their principal sources, while only 4% rely primarily on 
the internet. 
Conclusion: public awareness of the importance of cholesterol as a risk factor for cardio- 
vascular disease is high, but specific knowledge of cholesterol management is poor. 
Patients overwhelmingly identify physicians as their primary source of information. 
Therefore, physicians have an important opportunity to improve public understanding 
and management of lipid abnormalities, 
1202-90 Lowering LDL Cholesterol With Simvastatin, an HMG- 
CoA Reductese Inhibitor, Does Not Affect Luteal 
Function in Women 
NaDette Santoro, Diane Plotkin, Yale Mitchel, Joanna Waldstreicher, Minzhi Liu, Albert 
Einstein Col/ege of Medicine, Bronx, New York, Merck Research Laboratories, Rahway, 
New Jersey. 
Background: Cholesterol is the precursor of all steroid hormones, therefore cholesterol- 
reducing drugs could theoretically disrupt gonadal function in premenopausal women. 
Methods: This double-blind, randomized, placebo-controlled study was conducted to 
evaluate the effects of simvastatin treatment in premenopausal women. Normally cycling 
women (n=86) with elevated baseline LDL cholesterol (LDL-C) levels (130-250 mg/dL) 
were studied over six menstrual cycles. At the end of the screening phase (cycle #1), 
participants received placebo for the second menstrual cycle, and subsequently were 
randomized to receive either placebo (n=44) or simvastatin 40 mg/day (n=42) for the next 
four menstrual cycles (cycle #3-6). The second and sixth menstrual cycles were consid- 
ered baseline and treatment cycles, respectively. Participants kept a menstrual diary 
throughout he study, recording onset and duration of bleeding, and provided daily first- 
void urine samples (cycles #2 and 6). Urine samples were assayed for lutonizing hor- 
mone (LH) and pregnanediol glucuronide (PdG), the chief urinary metabolita of progest- 
erone. The primary endpoint was change in luteal phase duration as defined by the day 
of the urinary LH peak to the day preceding the onset of menstruation. The primary 
hypothesis was that there would not be a clinically significant decrease (4 days) in luteal 
phase duration between the treatment groups. 
Results'. Simvastatin Iowerad LDL-C and triglycerides by 34.3 (p<0.001) and 14.7% 
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(p<0.001), respectively, and raised high-density lipoprotein cholesterol by 4.9% 
(p<0.050). Simvastatin treatment had no clinically relevant effect on luteal phase dura- 
tion, peak PdG concentration, or integrated lutaal phase PdG concentration compared to 
the placebo group. Furthermore, the number of women experiencing anovulatory cycles 
or abnormal cycle lengths did not differ between the treatment groups. 
Conclualon: Treatment with simvastatin 40 mg/day was safe and effective at Iowedng 
LDL-C and did not adversely affect the hypothalamic-pituitary-gonadal axis in premeno- 
pausal women. 
ORAL CONTRIBUTIONS 
873 Venous Thromboembolisrn: Prevention 
and Treatment 
Tuesday, March 19, 2002, 4:00 p.m.-5:00 p.m. 
Georgia World Congress Center, Room 255W 
4:00 p.m. 
873-1 Lack of Association of Celecoxib With an Increased 
Risk of Thromboembollc Events 
Gerald Faich. l, E. Allen, S. D, Ross, James B. Lafkowith, Pharmaceutical Safety 
Assessments, Inc., Narberth, Pennsylvania, Metaworks, Inc., Medford, Massachusetts. 
Background: It has been hypothesized that COX-2 specific inhibitors may increase the 
risk of cardiovascular (CV) thromboembolic events because of their inhibition of vascular 
prostacyclin synthesis and lack of an effect on platelet aggregation. 
Methods: Data from the celecoxib clinical trial database were analyzed to deteEmine the 
incidence of sedous thromboembolic events (cardiac, cerebrovascular and peripheral 
vascular events) using a methodology derived from a recent FDA cardiorenal review 
(NDA 21-042, S-007). Since aspirin use for CV prophylaxis (<325 rag/d) was permitted, 
the analysis was performed for all patients and patients not taking aspirin, 
Results: The incidence rates, patient exposure and relative risk (RR) for the long term 
safety trial CLASS (duration 12-15 rod.), 15 controlled arthritis trials (durations 3-6 rod.) 
and the open label long term safety trial (duration 24-36 mo.) for celecoxib and NSAIDs 
(naproxen, diclofenac, ibuprofen) are shown in the following table (unadjusted for differ- 
ences in study demographics and cardiac risk factors). 
Conclusion: These data suggest that celecoxib is not associated with an increased inci- 
dence of serious thromboembolic events when compared to NSAIDs and thus do not 
support the hypothesis of a class effect of COX-2 specific inhibitors on CV events. 
Disclosure: Sponsored by Pharmacia Corporation and Pfizer Inc. 
Celecoxib NSAIDs RR (95% CI) 
CLASS Rate/100 pt-yrs (total patient exposure) 
All Patients 2.24 (2,320) 
Non-ASA 1.39 (1,804) 
Adhdtis Trials 
All 1.41 (2,845) 
Non-ASA 0.73 (2,587) 
Open Label Trial 
All 1.37 (7,024) 
Non-ASA 0.80 (5,720) 
2.22 (2,203) 1.01 (0.67-1.52) 
1.34 (1,715) 1.03 (0.56-1.91) 
1.59 (1,445) 0.88 (0.52-1.55) 
1.21 (1,325) 0.61 (0.30-1.26) 
Combined Trials (CLASS, Arthritis, Open Label) 
All 1.59 (11,693) 1.97 (3,648) 0.61 (0.61-1.07) 
Non-ASA 0.92 (9,677) 1.28 (3,040) 0.72 (0.49-1.07) 
4:15 p.m. 
873-2 Ominous Prognostic Implications and Inadequacy of 
Heparin Alone for Right Heart Thrombi in Patients With 
Acute Pulmonary Embolism: Analysis of Baseline 
Characteristics, Echocardiograms, Treatment, and 
Clinical Outcomes in the International Cooperative 
Pulmonary Embolism Registry 
Adam Torbicki, Samuel Z. Gctdhaber. Nazzareno Gali6, Anna Covezzoli, Madse De 
Rosa, on behalf of the ICOPER Study Group, Institute of Tuberculosis and Lung Disease, 
Warsaw, Poland. 
Background: Management of right heart thrombi (RHTh) in acute pulmonary embolism 
(PE) is controversial, because most reports have been small case series. Therefore, we 
analyzed 2, 454 consecutive acute PE patients enrolled in International Cooperative Pul- 
monary Embolism Registry (ICOPER). 
Methods: Of the 2,454 patients, 1,143 underwent baseline echocardiography. We com- 
pared the 42 patients with versus 1,071 without RHTh. 
Result,,: Patients with RHTh had lower systolic blood pressure (116.0.+_28.0 versus 
125.7..1:25.0 mmHg, p=0.008), especially < 90 mm Hg (14% versus 5%, p=0.012), and 
more frequent right ventdcular hypokinesis (64% versus 40%, p=0.002). However, they 
were similar at admission with respect to age (62.9 versus 62.5 years), arterial oxygen 
pressure (71.3+26.0 versus 69.5+30.5 mmHg), and prevalence of cancer (14% versus 
19%). The overall mortality rate at 14 days and at 3 months was twice as high in patients 
with RHTh (21% versus 11%, and 29% versus 16%, respectively, p<0.06) and remained 
so after the exclusion of patients with right heart catheters and electrodes potentially pro. 
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moting local thrombogenesis (mortality at 14 days 22% versus 10%, p = 0.026). interest- 
ingly, this difference in mortality was almost entirely observed within the subgroup of 
patients treated with heparin alone instead of lhrombolysis or embolectomy as adjuncts 
to heparin (25% versus 7.2%, p=0.007), despite similar clinical severity at presentation 
(systolic blood pressure 122.2+24.2 versus 127.8+24.1 mmHg, hypotension in 5.9% ver- 
sus 3.4%, and right ventricular hypokinesis in 52.5% versus 30.8% patients, respectively, 
all differences non-significant). 
Concluaions: RHTh confer an ominous prognosis with increased early mortality, espe- 
cially evident in patients treated with heparin alone. These findings suggest that patients 
with acute PE who have RHTh should be managed with more aggressive therapy than 
heparin anticoagulation alone, even when hemodynamically stable at the time of presen- 
tation. 
4:30 p.m. 
873-3 Compar i son  o f  Narrow Versus Standard Target INR 
Ranges 
David J. Mej@r, Seema S. Sonnad, Julie C. Merz, William P. Fay, University of Michigan, 
Ann Arbor, Michigan. 
Background: Although current guidelines suggest a target INR range of 2.0-3.0 or 2.5- 
3.5 for most patients, physicians frequently select narrow target INR ranges (e.g. 2.0-2.5) 
in an attempt to minimize complications. However, the efficacies of narrow versus stan- 
dard target INR ranges are unknown. We hypothesized that narrow range management 
results in a greater frequency of INRs <2.0 or >4.0. which are associated with an 
increased dsk of thrombotic and bleeding complications, respectively. 
Methods: We identified 32 patients managed with both a narrow and a standard range 
strategy during their course of anticoagulation. Over 3000 INRs during 133 patient-years 
of follow-up were obtained. Sixteen patients were managed with both a 2.0-3.0 and a 
2.0-2.5 range (Group A) and 16 patients were managed with both a 2.5-3.5 and a 3.0-3.5 
range (Group B). 
Results: Blood draws per month were more frequent (2.0_+0.2 vs. 1.7_+0.1 ; p=0.035) dur- 
ing narrow range management for both groups combined. For Group A, mean INR was 
lower (2.4_+0.03 vs. 2.6_+0.06; p<0.02) and frequency of INRs <2.0 was higher (23.6_+2.4 
vs. 17.2_+2.7; p<0.04) during narrow range management. For Group S, mean INR was 
higher (3.4±0.03 vs. 3,1±0.06; p<0.001) and frequency of INRs >4.0 was higher 
(21.2_+1.4 vs. 13.0±2.3; p<0.007) during narrow range management. 
Conclusions: Compared to a target INR range of 2.0-3.0, management with a target 
range of 2.0-2.5 increases the frequency of INRs <2.0, which are associated with an 
increased risk of thrombotic complications. Conversely, compared to a target range of 
2.5-3.5, management with a target range of 3.0-3.5 increases the frequency of INRs 
>4.0, which are associated with a significantly increased risk of hemorrhagic complica- 
tions. Narrow target INR ranges also increase the cost and patient inconvenience associ- 
ated with anticoagulant herapy. Physicians should take these issues into account before 
selecting narrow target INR ranges for their patients. 
4:45 p.m. 
873-4 Alteplase Improves the Clinical Course of  Pat ients  With 
Major Pulmonary Embolism: A Multicenter, 
Randomized, Placebo-Controlled Trial (Management 
Strategies  and Prognosis in Pulmonary Embolism 
Study 3) 
Stavros Konstantinides. Annette Geibel, Wolfgang Kasper, University of Goettingen, 
Department of Cardiology and Pulmonary Medicine, Goettingen, Germany, St. Josefs 
Hospital, Wiesbaden, Germany. 
Background: The clinical benefit of thrombolytic treatment in patients with major pulmo- 
nary embolism (PE) who appear stable at presentation remains highly controversial. 
Methods: In a prospective, multicenter, placebo-controlled trial, 250 consecutive patients 
with PE confirmed by lung scan, spiral CT, or pulmonary angiography were enrolled and 
247 of them randomly assigned to treatment with aiteplase (100 mg infusion over 2 h) 
plus heparin or heparin alone. Patients bad major PE defined as 1) echocardiographic 
findings of right ventdcular enlargement and/or pulmonary hypertension; 2) new-onset 
right heart strain on the ECG; or, 3) precapillary pulmonary hypertension on Swanz-Ganz 
catheterization. Patients with peristent arterial hypotension, cardiogenic shock, or need 
for cardiopulmonary resuscitation (CPR) at presentation were excluded. The primary end 
point was 30-day mortality or escalation/change of therapy (defined as need for breaking 
the code and/or one of the following: catecholamine infusion, endotracheal intubation, 
CPR, or emergency thrombolysis, catheter fragmentation, or surgical embolectomy) at 
least 2 h after randomization. 
Results: Alteplase was given to 115 (47%) and heparin alone to 132 (53%) pts. No dif- 
ferencas existed between the 2 groups with regard to the clinical symptoms, physical 
examination, radiologic, ECG, echocardiographic, or laboratory findings at randomiza- 
tion. The primary end point was reached in 31 pts (24%) of the heparin group compared 
with only 14 (12%) of those in the thrombolysis group (p=0.021). This difference was 
largely due to the more frequent need for escalation of therapy in the heparin vs. throm- 
bolysis group (24 vs. 11%; p=0.01), since mortality was iow in both groups (2 and 4 pts 
respectively; p=0.42). Major bleeding was 3% in the heparin and 0.9% in the aiteplase 
group (p=0.38), whereas hemorrhagic stroke occurred in only 1 patient (0.8%) in each 
group. 
Conclusion: In this largest to-date randomized trial of thrombolysis vs. heparin for PE, 
altaplase was found to favorably affect the clinical course of pts with major PE appearing 
hemodynamically stable at presentation, although it did not reduce in-hospital mortality. 
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881 Inflammation and Inflammatory Markers 
Wednesday, March 20, 2002, 8:30 a.m.-10:00 a.m. 
Georgia World Congress Center, Room 254W 
8:30 a.m. 
881-1 The Association Between In f lammatory  Markers and 
Thrombogenic Factors  in Pos t in fa rcUon Pat ients  
Tares S. Harb. Wojciech Zareba. Arthur J. Moss. Paul M. Ridker, Neder Ritai, Victor J. 
Marder, Luc Miller-Watelet, University of Rochester Medic.a/Center, Rochester, New 
York. 
Background: Dyslipidemia, inflammation and thrombosis are all implicated in the patho- 
physiology of plaque instability and rupture. To better understand the association among 
these mechanisms, we investigated the relationship between levels of inflammatory 
markers C-reactive protein (CRP) and serum amyloid A (SAA) and thrombogenic and 
lipid factors in patients with established coronary artery disease. 
Methods: Blood levels of CRP, SAA and various thrembogenic and lipid factors were 
measured 2 months after an index myocardial infarction in 957 patients. Multivariate 
analyses were used to determine the relationship between levels of inflammatory mark- 
ers and levels of lipid and thrombogenic factors. 
Results: In multivariate analysis, elevated CRP and SAA (->75 th pementile) were associ- 
ated with increased levels (p<0.00t) of several thrombogenic factors as summarized in 
the table below. Conversely, neither inflammatory marker was significantly associated 
with levels of lipid factors. 
Conclusion: In stable post-infarction patients, there is a significant association between 
levels of inflammatory markers and thrembogenic factors. Conversely, levels of inflam- 
matory markers are not significantly associated with the degree of dyslipidemia. This 
data suggests a possible mechanistic relationship between inflammation and thrombosis 
in patients with established coronary artery disease. 
Elevated CRP Elevated SAA 
OR CI* OR CI* 
vWF 2.21 1.50-3.25 2.79 1.88-4.14 
FIbrinogen 1,013 1,011-1,016 1.010 1.008-1.012 
D-Dlmer 1.85 t .46-2.35 2.10 1.65-2.68 
* - p<0.001 
vWF - von Willebrand Factor 
CI - 95% Confidence Interval 
OR - Odds Ratio (expressed per 1 log unit increase in vWF and D-Dimer and per 1 rag/ 
dl % increase in fibdnogen) 
8:45 a.m. 
881-2 C-Reactive Protein Predicts Microalbuminuria 
p.drian W. Messerli, Ravish Sachar, Gregory L. Pearce, Byron J. Hoogwerf, Dennis L 
Sprecher, The Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: Inflammation leads to endothelial dysfunction. It has been proposed that 
endothelial changes can lead to small losses of protein from the renal glomeruli. If C- 
reactive protein (CRP) is a marker for inflammation, then it may predict microalbuminuria. 
Methods: We analysed serum CRP and urine albumin/creatinine ratios (ACR) from 343 
patients (n=52, diabetics) drawn from our preventive cardiology clinic. ACR values >20 
mg/g were used as the cutpoint, approximating the upper quartile presented in the HOPE 
trial. Quinfiles of CRP from our population were utilized. Results: Logistic regression 
models were constructed to determine the relative risk of microalbuminuria ssociated 
with each quintile increase in CRP. Three models were run: (1) unadjusted, (2) Framing- 
ham adjusted, and (3) Framingham + CAD status adjusted. All three models show that 
CRP partially explains the level of microalbuminuria for each successive CRP quintile 
(see table). In contrast to a previous cohort analysis, further adjustment for fibrinogen, 
waist, and glucose level did not change the outcome. Conclusions: Each progressively 
higher CRP quartile predicts an additional 30% risk for the presence of microalbuminuria. 
These data are consistent with and further substantiate the relationship between inflam- 
mation and renovascular endothelial dysfunction. 
Logistic regression of RR for ACR >20 mg/g 
DM ALL 
OR (95% C.I) p-value OR (95% C.I.) p-value 
Unadjusted 2.08 (1.15-3.68) 0.01 1.38 (1.12-1.72) 0.003 
Framingham Adjustment 2.06 (1.16-3.66) 0.01 1.31 (1.05 - 1.63) 0.02 
Framingham + CAD 2.05 (1.15-3.67) 0.02 1.32 (1.05-1.66) 0.02 
